Niagen Bioscience Inc (NASDAQ:NAGE - Get Free Report)'s stock price hit a new 52-week high during trading on Tuesday after Canaccord Genuity Group raised their price target on the stock from $13.00 to $16.00. Canaccord Genuity Group currently has a buy rating on the stock. Niagen Bioscience traded as high as $13.53 and last traded at $13.43, with a volume of 1329467 shares trading hands. The stock had previously closed at $12.95.
Other equities research analysts also recently issued reports about the company. Wall Street Zen downgraded Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Roth Capital restated a "buy" rating and set a $23.00 price objective (up from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th.
View Our Latest Stock Report on NAGE
Niagen Bioscience Stock Performance
The firm has a market capitalization of $1.07 billion, a P/E ratio of 80.18 and a beta of 2.08. The stock has a fifty day moving average price of $9.25 and a two-hundred day moving average price of $7.12.
About Niagen Bioscience
(
Get Free Report)
Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
Read More
Before you consider Niagen Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Niagen Bioscience wasn't on the list.
While Niagen Bioscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
